A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

• मुख्य लेखकों: Vishnu Eshwar (लेखक), Ashwin Kamath (लेखक), Rajeshwari Shastry (लेखक), Ashok K. Shenoy (लेखक), Priyanka Kamath (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2022-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...